BREAKING NEWS
Fed slashes interest rates by 25 basis points in 2nd consecutive cut
NasdaqGS - Nasdaq Real Time Price USD
CytomX Therapeutics, Inc. (CTMX)
As of 2:30 PM EST. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 6 | 7 | 7 |
| Avg. Estimate | -0.17 | -0.2 | -0.31 | -0.61 |
| Low Estimate | -0.28 | -0.31 | -0.53 | -1.1 |
| High Estimate | -0.09 | -0.11 | -0.11 | -0.46 |
| Year Ago EPS | 0.04 | 0.01 | -0.01 | -0.31 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | 17.51M | 15.09M | 101.17M | 75.98M |
| Low Estimate | 8M | 6.1M | 82M | 31M |
| High Estimate | 25.1M | 25M | 119.76M | 102M |
| Year Ago Sales | 14.14M | 26.61M | 101.21M | 101.17M |
| Sales Growth (year/est) | 23.80% | -43.30% | -0.00% | -24.90% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.19 | -0.03 | -0.08 | -0.14 |
| EPS Actual | 0.04 | 0.01 | 0.17 | -0.08 |
| Difference | 0.23 | 0.04 | 0.25 | 0.06 |
| Surprise % | 121.10% | 133.30% | 312.50% | 42.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.17 | -0.2 | -0.31 | -0.61 |
| 7 Days Ago | -0.17 | -0.2 | -0.31 | -0.61 |
| 30 Days Ago | -0.17 | -0.2 | -0.31 | -0.61 |
| 60 Days Ago | -0.17 | -0.2 | -0.31 | -0.61 |
| 90 Days Ago | -0.14 | -0.13 | -0.35 | -0.55 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CTMX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -525.00% | -- | -- | 5.40% |
| Next Qtr. | -2,100.00% | -- | -- | 12.70% |
| Current Year | -3,000.00% | -- | -- | 2.10% |
| Next Year | -96.80% | -- | -- | 12.30% |
| Next 5 Years (per annum) | -0.90% | -- | -- | 11.06% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Neutral | 9/13/2024 |
| Reiterates | HC Wainwright & Co.: Neutral | 8/22/2024 |
| Reiterates | HC Wainwright & Co.: Neutral | 6/27/2024 |
| Upgrade | Piper Sandler: Neutral to Overweight | 5/28/2024 |
| Maintains | BMO Capital: Market Perform to Market Perform | 5/9/2024 |
| Reiterates | HC Wainwright & Co.: Neutral | 5/9/2024 |
Related Tickers
ASMB Assembly Biosciences, Inc.
16.89
+1.44%
SPRO Spero Therapeutics, Inc.
1.3100
0.00%
MRSN Mersana Therapeutics, Inc.
2.5200
+7.69%
MGNX MacroGenics, Inc.
4.5800
+9.31%
ATRA Atara Biotherapeutics, Inc.
10.11
+1.05%
ALXO ALX Oncology Holdings Inc.
1.5050
-1.63%
KPTI Karyopharm Therapeutics Inc.
0.9074
+2.35%
KALA KALA BIO, Inc.
7.00
-0.14%
FGEN FibroGen, Inc.
0.3187
+2.67%
PIRS Pieris Pharmaceuticals, Inc.
16.52
-1.17%